ËÄÉ«AV

Ìý

Susana SaldanhaÌýand Mirjam KoblerÌýwill present and share the relevant aspects of developing a Dry Powder Inhaler (DPI), from formulation to device development, also showcasing different approaches to enable efficient delivery of traditional carrier-based formulations as well as more advanced formulations containing engineered particles. Join the conversation and ask your questions during the live Q&A session!

Featured speakers in this webinar
	Susana Saldanha, M.Sc. R&D Manager, Inhalation and Advanced Drug Delivery at ËÄÉ«AV Susana Saldanha holds a PharmD from Faculty of Pharmacy, University of Coimbra. She has over 11 years of experience in formulation development. She has supported the development of oral, transdermal, and injectable dosage forms, spanning from early drug product development through product registration to launch. In 2018, she joined ËÄÉ«AV where she focused not only on drug delivery to the lungs but also nasal and ophthalmic drug delivery. She worked on drug product development projects from early to later stages, ranging from generics to innovative products. Currently, she works as R&D manager in the Inhalation and Advanced Drug Delivery Group.
	Mirjam Kobler, Ph.D. Global Business Development Manager at H&T Presspart Mirjam Kobler, Ph.D., is currently Global Business Development Manager forH&T Presspart. Dr Kobler oversees the management and business development activities for H&T Presspart’s DPI device portfolio. Before joining H&T Presspart Dr Kobler worked at Meggle, where she headed the R&D Department of Meggle’s Excipients and Technology business group. Dr Kobler’s background includes seven years of experience in various areas of lactose excipients, especially for DPIs.

This webinar will provide a clear picture of how device design and formulation development can be tuned to meet the different challenges in powder formulations.

Dry Powder Inhalers are widely used for the treatment of local diseases, like Asthma and COPD and in recent years more and more applications for systemic delivery have been explored. This opens a wide potential, but also great challenges for developing Dry Powder Inhalers. There is a fine interplay between formulations, processes as well as devices to deliver drugs efficiently and consistently to the lungs. This is relevant for developing a classic low dose Asthma /COPD DPI, as well as for a new developments involving challenging powders used in higher doses. An integrated development approach of formulation and device is crucial to overcome the challenges, such as insufficient and inconsistent emitted dose and lung deposition across different flowrates.

During our presentation we want to outline the relevant aspects of developing a Dry Powder Inhaler ranging from formulation to device development. Showcasing different approaches to enable efficient delivery of traditional carrier-based formulations as well as more advanced formulations containing engineered particles. The first part focuses on low dose carrier-based formulations and how by adjusting formulation and device the aerodynamic performance can be tuned. The second part will showcase engineered particle platforms tailored to various API properties and their interaction with the device for an optimized performance and drug delivery.

Ìý

Key Learning Objectives:

• Challenges in DPI development
• High dose and low dose formulation tools
• High dose formulation platforms for efficient delivery
• Capsule-based DPI device development

Who Should Attend:

• Pharmaceutical researchers and scientists
• CMC experts on inhalation drug delivery
• Business development, portfolio management and technology licensing experts
• Inhalation product development professionals
• Respiratory therapeutics specialists

Ìý

Ìý